Anti-Coagulants - LATAM
LATAM- Revenue in the Anti-Coagulants market is projected to reach US$1.29bn in 2024.
- Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 7.82%, resulting in a market volume of US$1.75bn by 2028.
- In global comparison, most revenue will be generated United States (US$16.74bn in 2024).
- Key regions:
- Australia,
- Japan,
- United States,
- Germany,
- Europe
Definition:
The Anti-Coagulants market covers drugs that prevent blood from clotting, i.e., that prolong the clotting time. Anti-coagulants are certain types of antithrombotics, which are often also called blood thinners. Neither thrombolytic drugs, which dissolve clots after they have formed, nor other anti-thrombotics, such as antiplatetelet drugs, are covered in this market.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Company examples: Bristol Myers Squibb, Bayer, Sanofi, Johnson & Johnson
In-Scope
- Blood clotting inhibitors
Out-Of-Scope
- Anti-fibrinolytics
- Anti-hypertensives
- Other hematology drugs
- Other anti-thrombotic agents, such as platelet aggregation inhibitors
- Thrombolytic drugs
